title: [The use of Octreotide-depo for the pancreatitis' prophylaxis after radical surgery of gastric cancer with lymphadenectomy].
abstract: The efficacy of the medicamentous prophylaxis of the acute postoperative pancreatitis (APP) was estimated in 594 patients. They all were divided into 3 groups: 1st was treated with octreotide, 2nd - with octreotide-depo, 3rd - with 5-ftoruracil and dalargin. Patients of the 3rd group showed the highest levels of α-amylase in both blood and drainage fluid during the early postoperative period. The frequency and severity of postoperative complication rates were the lowest in those patients, who received octreotide-depo and was 3,06%; whereas among patients of the 2nd group it was 16,8% and among those, who were treated with 5-ftoruracil and dalargin, it was 22,4%. The destructive forms of pancreatitis were registered in 2nd and 3rd groups in 1 and 3 patients, respectively. Intraabdominal abscesses were registered in 1 patient of the 1st and 6 patients of the 3rd group, respectively. The lethality rate was 0.9% in the 1st group; 1.02% in the 2nd and 1.8% in the 3rd group. The use of somatostatine analogues in the prophylaxis of postoperative complications proved to decrease overall complications' rate and, first of all, the rate of postoperative destructive pancreatitis. The use of the prolonged forms of somatostatine analogues, i.e., octreotide depo 10 mg is considered to be highly effective.
authors.forename: A F
authors.initials: AF
authors.lastname: Chernousov
authors.forename: A V
authors.initials: AV
authors.lastname: Egorov
authors.forename: F A
authors.initials: FA
authors.lastname: Chernousov
authors.forename: V V
authors.initials: VV
authors.lastname: Levkin
authors.forename: D V
authors.initials: DV
authors.lastname: Vychuzhanin
authors.forename: N S
authors.initials: NS
authors.lastname: Kharlov
authors.forename: S N
authors.initials: SN
authors.lastname: Stepanov
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy / Q000009:adverse effects* / Q000379:methods; D005765:Gastrointestinal Agents / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008197:Lymph Node Excision / Q000009:adverse effects* / Q000379:methods; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D019283:Pancreatitis, Acute Necrotizing / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000556:secondary / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide